Herein, we described the preclinical efficacy and non-human primate toxicology profile of the monovalent high-affinity and bivalent low-affinity anti-LYPD1 TCBs that selectively target tumor cells expressing the PAX8 lineage-driven cell surface antigen LYPD1 in HGSOC. This evidence concerns the gene PAX8 and neoplasm.